TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Renalytix ( (GB:RENX) ) has issued an update.
Renalytix announced the publication of pivotal data on its kidneyintelX.dkd test in the Diabetes Care Journal, highlighting its clinical utility in chronic kidney disease management. The study demonstrated that the test provides improved risk classification and significant risk reduction when used with SGLT2i therapy, supporting personalized patient care. The publication coincides with presentations at the American Society of Nephrology Kidney Week, reinforcing the test’s value in precision medicine and integrated care management, ultimately leading to better patient outcomes.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has received FDA approval and Medicare reimbursement for its kidneyintelX.dkd test, which is now commercially available in the United States. This test is the only FDA-approved prognostic tool for early-stage risk assessment in chronic kidney disease, helping to address the significant challenge of unrecognized and uncontrolled kidney disease in the US and UK.
Average Trading Volume: 5,134,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: £31.68M
Learn more about RENX stock on TipRanks’ Stock Analysis page.